Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease.

Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS.

Clin Kidney J. 2012 Feb;5(1):82-88.

2.

Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.

Wiginton CD, Kelly B, Oto A, Jesse M, Aristimuno P, Ernst R, Chaljub G.

AJR Am J Roentgenol. 2008 Apr;190(4):1060-8. doi: 10.2214/AJR.07.2822.

PMID:
18356456
3.

Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).

Bennett CL, Starko KM, Thomsen HS, Cowper S, Sartor O, Macdougall IC, Qureshi ZP, Bookstaver PB, Miller AD, Norris LB, Xirasagar S, Trenery A, Lopez I, Kahn A, Murday A, Luminari S, Cournoyer D, Locatelli F, Ray P, Mattison DR.

J Gen Intern Med. 2012 Dec;27(12):1697-703. doi: 10.1007/s11606-012-2098-1. Epub 2012 Jun 13. Review.

4.

Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.

Elmholdt TR, Pedersen M, Jørgensen B, Søndergaard K, Jensen JD, Ramsing M, Olesen AB.

Br J Dermatol. 2011 Oct;165(4):828-36. doi: 10.1111/j.1365-2133.2011.10465.x.

PMID:
21692765
5.

High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent.

Rydahl C, Thomsen HS, Marckmann P.

Invest Radiol. 2008 Feb;43(2):141-4. doi: 10.1097/RLI.0b013e31815a3407.

PMID:
18197066
6.

Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned.

Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA.

AJR Am J Roentgenol. 2007 Feb;188(2):586-92.

PMID:
17242272
7.

Nephrogenic systemic fibrosis: center case review.

Lauenstein TC, Salman K, Morreira R, Tata S, Tudorascu D, Baramidze G, Singh-Parker S, Martin DR.

J Magn Reson Imaging. 2007 Nov;26(5):1198-203. Review.

PMID:
17969162
8.

Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.

Tsushima Y, Kanal E, Thomsen HS.

Br J Radiol. 2010 Jul;83(991):590-5. doi: 10.1259/bjr/17689538. Epub 2010 Apr 22. Review.

9.

An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital.

Marckmann P.

Eur J Radiol. 2008 May;66(2):187-90. doi: 10.1016/j.ejrad.2008.01.032. Epub 2008 Mar 6.

PMID:
18328659
10.

[Nephrogenic systemic fibrosis].

Breitschaft A, Stahlmann R.

Med Monatsschr Pharm. 2009 Oct;32(10):377-82. Review. German.

PMID:
19886227
11.

Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases.

Zou Z, Ma L.

Indian J Dermatol. 2011 Jan;56(1):65-73. doi: 10.4103/0019-5154.77556.

12.

Incidence of nephrogenic systemic fibrosis at two large medical centers.

Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, DeLapaz RL, Lee HJ, Magro CM, Valeri AM.

Radiology. 2008 Sep;248(3):807-16. doi: 10.1148/radiol.2483071863.

PMID:
18710976
13.

Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.

Altun E, Martin DR, Wertman R, Lugo-Somolinos A, Fuller ER 3rd, Semelka RC.

Radiology. 2009 Dec;253(3):689-96. doi: 10.1148/radiol.2533090649. Epub 2009 Sep 29.

PMID:
19789233
14.

Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.

Soulez G, Bloomgarden DC, Rofsky NM, Smith MP, Abujudeh HH, Morgan DE, Lichtenstein RJ, Schiebler ML, Wippold FJ 2nd, Russo C, Kuhn MJ, Mennitt KW, Maki JH, Stolpen A, Liou J, Semelka RC, Kirchin MA, Shen N, Pirovano G, Spinazzi A.

AJR Am J Roentgenol. 2015 Sep;205(3):469-78. doi: 10.2214/AJR.14.14268.

PMID:
26295633
15.

Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.

Edwards BJ, Laumann AE, Nardone B, Miller FH, Restaino J, Raisch DW, McKoy JM, Hammel JA, Bhatt K, Bauer K, Samaras AT, Fisher MJ, Bull C, Saddleton E, Belknap SM, Thomsen HS, Kanal E, Cowper SE, Abu Alfa AK, West DP.

Br J Radiol. 2014 Oct;87(1042):20140307. doi: 10.1259/bjr.20140307.

16.

Application of gadolinium-based contrast agents and prevalence of nephrogenic systemic fibrosis in a cohort of end-stage renal disease patients on hemodialysis.

Becker S, Walter S, Witzke O, Kreuter A, Kribben A, Mitchell A.

Nephron Clin Pract. 2012;121(1-2):c91-4. doi: 10.1159/000345150. Epub 2012 Nov 22.

PMID:
23182840
17.

Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control study.

Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J.

Rheumatology (Oxford). 2014 Sep;53(9):1613-7. doi: 10.1093/rheumatology/keu151. Epub 2014 Apr 4.

18.

Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis.

Agarwal R, Brunelli SM, Williams K, Mitchell MD, Feldman HI, Umscheid CA.

Nephrol Dial Transplant. 2009 Mar;24(3):856-63. doi: 10.1093/ndt/gfn593. Epub 2008 Oct 24. Review.

PMID:
18952698
19.

Risk factors for developing gadolinium-induced nephrogenic systemic fibrosis.

Peak AS, Sheller A.

Ann Pharmacother. 2007 Sep;41(9):1481-5. Epub 2007 Aug 7. Review.

PMID:
17684032
20.

Nephrogenic systemic fibrosis: review of 370 biopsy-confirmed cases.

Zou Z, Zhang HL, Roditi GH, Leiner T, Kucharczyk W, Prince MR.

JACC Cardiovasc Imaging. 2011 Nov;4(11):1206-16. doi: 10.1016/j.jcmg.2011.08.013. Review.

Supplemental Content

Support Center